ERBB2 and cancer: Compared with Basal-like BRCA, Luminal A and B and Her2-enriched cancer had a slightly higher CS in terms of the TSC/mTOR pathway (Basal-like: 0.3; Luminal A and B: 0.6; Her2-enriched: 0.4).